Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333151 · ClinicalTrials.gov registry record · Phase 3
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 576
- Enrollment target
NCT00333151: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT00333151 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 576 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00333151, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 576 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.
Interventions
- DRUG metformin
- DRUG liraglutide
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00333151 record still lists
NCT00333151 is an interventional study that assigns participants to a tested intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT00333151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00333151 about?
NCT00333151 is a clinical study titled "Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes". This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alon...
What is the current status of trial NCT00333151?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2006-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00333151?
The interventions under investigation include: metformin (DRUG), liraglutide (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00333151?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00333151's enrollment target sits among peer trials
576 661st of 2000 higher than 1,340 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia